Industry
Biotechnology
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Loading...
Open
5.38
Mkt cap
200M
Volume
29K
High
5.38
P/E Ratio
-3.29
52-wk high
11.69
Low
5.05
Div yield
N/A
52-wk low
4.22
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 11:41 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 8:38 pm
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 5:29 pm
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 11:39 am
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 9:00 pm
Portfolio Pulse from Benzinga Insights
May 02, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 12:49 pm
Portfolio Pulse from Happy Mohamed
March 28, 2024 | 3:46 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.